Advanced Oncotherapy

Advanced Oncotherapy is a specialist developer and provider of the next generation of particle therapy systems that makes radiation less toxic for patients. Our aim is to create a bright future in cancer care with our advanced LIGHT technology. Vision: To develop a more affordable proton-based radiotherapy system, using an innovative and clinically more effective technology, and saving more cancer lives. Mission: To facilitate the wider use of radiation with protons for treating all forms of radio-sensitive cancers by commercialising a novel technology, and building on the success and scientific know-how of CERN (Centre Européen pour la Recherche Nucléaire).
London, GB
Size (employees)
51 (est)
Advanced Oncotherapy was founded in 1994 and is headquartered in London, GB

Advanced Oncotherapy Office Locations

Advanced Oncotherapy has offices in London, Syracuse, Rolle
London, GB (HQ)
4-7 Manchester St
Rolle, CH
23 Route de Genève
Syracuse, US
1009 E Fayette St

Advanced Oncotherapy Metrics

Advanced Oncotherapy Financial Metrics

Revenue (2015)

£84.2 k

Revenue growth (2014-15), %


Gross profit

(£25.5 k)

Gross profit margin (2015), %


Net income (2015)

(£5.8 m)

Market capitalization (22-Mar-2017)

£20.4 m

Closing share price (22-Mar-2017)


Cash (31-Dec-2015)

£9 m
Advanced Oncotherapy's current market capitalization is £20.4 m.
Advanced Oncotherapy's revenue was reported to be £84.2 k in FY, 2015 which is a 20.8% decrease from the previous period.
FY, 2013FY, 2014FY, 2015


£68.9 k£106.4 k£84.2 k

Revenue growth, %


Cost of goods sold

£156 k£202.7 k£109.7 k

Gross profit

(£87 k)(£96.3 k)(£25.5 k)

Gross profit Margin, %


Operating expense total

£3.1 m£5.7 m£8.5 m

Pre tax profit

(£3.4 m)(£5.7 m)(£8.6 m)

Net Income

(£3.4 m)(£5.7 m)(£5.8 m)
FY, 2013FY, 2014FY, 2015


£148.8 k£1.5 m£9 m

Accounts Receivable

£28.6 k£73.6 k

Current Assets

£1.4 m£3.2 m£16.7 m


£2.7 m£2.1 m£1.3 m


£8.2 m£9.2 m£12.7 m

Total Assets

£12.3 m£14.5 m£30.7 m

Accounts Payable

£722.5 k£1.1 m£342 k

Current Liabilities

£5.4 m£3.3 m£3.5 m

Retained Earnings

(£3.9 m)(£7.5 m)(£6.6 m)

Total Equity

£6.9 m£11.1 m£27.3 m

Financial Leverage

1.8 x1.3 x1.1 x
FY, 2013FY, 2014FY, 2015

Cash From Operating Activities

(£2.9 m)(£6.6 m)(£9.8 m)

Cash From Financing Activities

£2.5 m£9.2 m£21.1 m

Income Taxes Paid

£2.8 m

Advanced Oncotherapy Market Value History

Advanced Oncotherapy Online Presence

Advanced Oncotherapy News

Advanced Oncotherapy Company Life

You may also be interested in